LEADER 01561nam  2200397   450 
001 9910715097603321
005 20221025075534.0
035   $a(CKB)4100000011920094
035   $a(NjHacI)994100000011920094
035   $a(OCoLC)1202625853$z(OCoLC)1227256149
035   $a(EXLCZ)994100000011920094
100   $a20221025d2019      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aRisk of nephrogenic systemic fibrosis after exposure to newer gadolinium agents /$fKaren M. Goldstein [and two others]
210  1$aWashington, DC :$cU.S. Department of Veterans Affairs, Veterans Health Administration, Health Services Research & Development Service,$d2019.
215   $a1 online resource (vi, 111 pages) $cillustrations
225 1 $aEvidence-based synthesis program (Series)
300   $a"October 2019."
320   $aIncludes bibliographical references.
410  0$aEvidence-based synthesis program (Series)
606   $aContrast media (Diagnostic imaging)
607   $aUnited States$2fast
615  0$aContrast media (Diagnostic imaging)
676   $a572
700   $aGoldstein$b Karen M.$01353976
712 02$aUnited States.$bDepartment of Veterans Affairs.$bHealth Services Research and Development Service,
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910715097603321
996   $aRisk of nephrogenic systemic fibrosis after exposure to newer gadolinium agents$93291168
997   $aUNINA